.png)
.jpg)
.png)
.png)
Viral hepatitides and human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) are significant public health problems. Globally, there are an estimated 1.34 million deaths annually due to viral hepatitis and 1.33 million due to HIV/AIDS. Viruses transmitted through blood, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV), are highly prevalent among intravenous drug using (IDU) individuals. This study aimed to investigate the seropositivity rates of antibody to HCV (anti-HCV), HBsAg, and antibody to HIV (anti-HIV), along with sociodemographic and clinical characteristics, in patients diagnosed with opioid use disorder undergoing inpatient detoxification treatment at the Alcohol and Drug Addiction Treatment Center (ADATC). The patients diagnosed with Opoid Use Disorder and treated in Inpatient unit between January 1, 2016, and January 1, 2018, were retro spectively reviewed. In the serological analysis results, anti-HCV positivity was found in 50 (8.2%) patients, and HBsAg positivity was detected in seven (1.1%) patients, with no cases of anti-HIV positivity observed. Regarding anti-HCV positivity, statistically significant differences were found among subgroups related to the age at first substance use, age at first opioid use, history of intravenous drug use, and city of residence. However, no statistically significant differences were observed among subgroups related to age, gender, marital status, education level, employment status, legal history, and additional substance use history.
Cite this article as: Paltun, S. C. (2025). Seropositivity rates of anti-HCV, HbsAg, anti-HIV and the relationship between sociodemographic and clinical variables in individuals hospitalized with a diagnosis of opioid use disorder. Addicta: The Turkish Journal on Addictions, 12(1), 58-62.